Peng Xiao-Mou, Gu Lin, Chen Xue-Juan, Li Jian-Guo, Huang Yang-Su, Gao Zhi-Liang
Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China.
World J Gastroenterol. 2005 Jun 21;11(23):3614-8. doi: 10.3748/wjg.v11.i23.3614.
To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.
Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control. To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CD-PCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection.
The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to 10 micromol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain independent of the amount of templates and the number of PCR cycles. Its detection limit was 10(3) copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg.
Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.
改进竞争性差异聚合酶链反应(CD-PCR)用于检测乙型肝炎病毒(HBV)核心启动子突变。
将通过定点诱变构建的HBV核心启动子双点突变A1762T/G1764A的重组质粒用作突变对照。为揭示CD-PCR的缺陷机制,比较研究了PCR循环数与各竞争性引物产物增长速度之间的关系。尝试通过改变dNTPs的量和竞争性引物的相互引物来优化CD-PCR。通过检测重组质粒和HBV感染患者临床血清中的A1762T/G1764A突变来评估优化后的CD-PCR。
CD-PCR的缺陷机制是当匹配引物的扩增进入平台期时,错配竞争性引物的产物增长迅速,导致其产物量的差异减小或消失。将dNTPs降至10微摩尔/升,相互引物降至约100纳摩尔/升可消除此现象。优化后的CD-PCR可独立于模板量和PCR循环数检测突变株和野生株。其检测限为10³拷贝/毫升,约50拷贝/反应。可检测野生型DNA中约10%的突变DNA。在41.8%(51/122)的HBV感染患者中检测到A1762T/G1764A突变,而在HBsAg阴性的对照中未检测到。
优化后的CD-PCR可独立于初始模板量和PCR循环数检测突变。